Australia's TGA Warns of Anaphylaxis Risks in Cold Supplements

0:00It's April 9th. This is Sydney News Today, powered by AI. I'm Cory with the story. Australia's therapeutic goods administration just dropped a bomb show on Andrographis Paniculata that herb popping up in about 84 cold and flu supplements. They say it's tied to serious anaphylaxis risks, the kind that can straight up threaten lives. These are low-risk listed medicines you grab off pharmacy shelves to fight sniffles or boost immunity. But the TGA safety review calls it a mismatch for that category. Since 2005, they've logged 1,368 adverse reactions, including 287 anaphylaxis cases. Warnings kicked in back in 2019 and a big-maker updated labels last August to flag anaphylaxis, but reports stayed sky-high through 20, 24, and into this year. Bottom line, labels end cutting it for first-timers or repeat users' hit with unpredictable hits. Experts like Professor Connie Catellaris from Western Sydney University been sounding

1:03alarms for years, saying the harm outweighs any upsides with global data backing in. Victims like Carmen Wells, who got liver damage back in 2019 from a cold supplement, still deal with health checks six years later. He's glad for the review, but frustrated. It took so long after a fatal reaction sparked it last July. Now the TGA's consulting docs, makers, and consumer groups on yanking and geographies from the low-risk ingredient list, consultation wrapped April 30th. Critics slammed the delay, arguing the data's clear and expert panels already greenlit action months ago. Biosuiticles, behind-hit-protted armor force, says they're watching and prioritizing safety. This move won't touch prescription or higher-risk meds, but for over-the-counter cold fighters, it could mean big changes ahead. Keep an eye on those labels, folks. Better safe than sorry when chasing that flu relief.